TY - JOUR
T1 - Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
AU - Sandri, Maria Teresa
AU - Johansson, Harriet Ann
AU - Zorzino, Laura
AU - Salvatici, Michela
AU - Passerini, Rita
AU - Maisonneuve, Patrick
AU - Rocca, Andrea
AU - Peruzzotti, Giulia
AU - Colleoni, Marco
PY - 2007/8/1
Y1 - 2007/8/1
N2 - BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P
AB - BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P
KW - EGFR
KW - Her-2/neu
KW - Metastatic breast cancer
KW - Metronomic therapy
KW - Serum biomarker
UR - http://www.scopus.com/inward/record.url?scp=34547097500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547097500&partnerID=8YFLogxK
U2 - 10.1002/cncr.22825
DO - 10.1002/cncr.22825
M3 - Article
C2 - 17559147
AN - SCOPUS:34547097500
VL - 110
SP - 509
EP - 517
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 3
ER -